The strong U.S. launch trajectory for IMCIVREE in acquired HO and positive RM-718 data support a re-rating of the commercial opportunity. Monitor upcoming catalysts: Japan MHLW decision on IMCIVREE for HO by year-end 2026, Phase 3 bivamelagon trial initiation, and RM-718 Part D enrollment completion. The narrowed OpEx guidance provides cost visibility.
Drug in focus
RYTM drug pipeline →IMCIVREE
▲ Bullish Named in this press release- Impact
- Not rated
- Phase
- Not stated
- Time to market
- Not stated
- Next catalyst
- None dated
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 4 $105.78entry
- T+1 · 3mo ago +4.66%α +4.86% · $110.71
- T+5 · 3mo ago +6.68%α +6.78% · $112.85
- T+20 · 3mo ago −0.98%α +0.25% · $104.74
- T+60 · 20d ago −12.86%α −12.64% · $92.18
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M (vs $67.7M consensus, +5.3% beat) and a GAAP EPS loss of -$0.73 (vs -$0.83 consensus, a 12.0% beat), driven by a strong U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO). The company also announced positive preliminary Phase 2 data for its weekly injectable MC4R agonist RM-718, showing an -11.6% mean BMI reduction at 16 weeks, and narrowed its 2026 Non-GAAP OpEx guidance to $363M-$397M (from $385M-$415M). The combination of a top- and bottom-line beat, accelerating U.S. revenue growth (+38% QoQ), and encouraging pipeline data is a clear positive signal for the commercial story and long-term growth trajectory.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $71.3M vs consensus $67.7M (+5.3% beat)
- GAAP EPS -$0.73 vs consensus -$0.83 (+12.0% beat)
- U.S. IMCIVREE revenue $51.0M, up 38% QoQ from Q1 2026
- Over 400 patient start forms for IMCIVREE in acquired HO since FDA approval
- RM-718 Phase 1/2 data: -11.6% mean BMI reduction at 16 weeks in acquired HO (n=7)
- 2026 Non-GAAP OpEx guidance narrowed to $363M-$397M from $385M-$415M
- Cash position $330.9M, sufficient for at least 24 months
Financial Impact
Revenue beat of $3.6M (+5.3%) and EPS beat of $0.10 (+12.0%) vs consensus; U.S. revenue growth of $14.1M (+38%) QoQ
Risk Factors
- Ex-U.S. revenue declined 13% QoQ due to a $3.8M retrospective charge in France
- Net loss widened to $50.4M in Q2 2026 from $48.0M in Q2 2025
- SG&A expenses rose 47% YoY to $67.4M, outpacing revenue growth
- Dependence on acquired HO launch for near-term growth; competitive risk from other MC4R agonists
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3338168 |
Track record
26 reports on RYTM
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $115.02 +7.02% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $115.02 +3.92% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $115.02 +3.92% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $115.02 +33.06% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $115.02 +33.06% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $115.02 +32.65% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $115.02 +32.80% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $115.02 −18.86% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $115.02 +0.20% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers